Alvotech (ALVO) has released an update.
Alvotech announces the European Medicines Agency’s acceptance of their Marketing Authorization Application for AVT03, a biosimilar candidate to osteoporosis treatments Prolia and Xgeva. This step is significant for expanding patient access in Europe to cost-effective biologic medicines. The European denosumab market, which AVT03 aims to enter, is currently valued at approximately US$1 billion.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
